Tandem Diabetes Care (LTS:0M0F) ROCE %: -9.46% (As of Mar. 2026)

What is Tandem Diabetes Care ROCE %?

Tandem Diabetes Care LTS:0M0F +0.95% 67 ROCE % is -9.46% as of Mar. 2026. GuruFocus rates LTS:0M0F with a GF Score™ of 67/100 and a GF Value™ of $29.23 (Possible Value Trap). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tandem Diabetes Care's annualized ROCE % for the quarter that ended in Mar. 2026 was -9.46%.

Tandem Diabetes Care (LTS:0M0F) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Tandem Diabetes Care ROCE % Related Terms

Tandem Diabetes Care ROCE % Historical Data

* Premium members only.

The historical data trend for Tandem Diabetes Care's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tandem Diabetes Care ROCE % Chart

Tandem Diabetes Care Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

2.92

-10.66

-25.80

-11.69

-28.58

Tandem Diabetes Care Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-71.30	-35.09	-14.82	3.11	-9.46

67GF Score

Tandem Diabetes Care Inc LTS:0M0F

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Tandem Diabetes Care ROCE % Calculation

Tandem Diabetes Care's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-194.225	/	( ( (967.658 - 247.049)	+	(881.112 - 242.724) )	/ 2 )
	=	-194.225	/	( (720.609	+	638.388)	/ 2 )
	=	-194.225	/	679.4985
	=	-28.58 %

Tandem Diabetes Care's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-72.996	/	( ( (881.112 - 242.724)	+	(1153.394 - 247.959) )	/ 2 )
	=	-72.996	/	( ( 638.388	+	905.435 )	/ 2 )
	=	-72.996	/	771.9115
	=	-9.46 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -9.46% mean?

Tandem Diabetes Care (LTS:0M0F) has a ROCE % of -9.46% as of Mar. 2026.

Is Tandem Diabetes Care's ROCE % too high?

Tandem Diabetes Care's current ROCE % is -9.46%. Overall, Tandem Diabetes Care has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Tandem Diabetes Care's ROCE % compare to ATEC and BFLY?

Tandem Diabetes Care's ROCE % of -9.46% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tandem Diabetes Care's current ROCE % is -9.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Tandem Diabetes Care stock overvalued right now?

Based on GuruFocus' analysis, Tandem Diabetes Care (LTS:0M0F) is currently considered Possible Value Trap. The stock's GF Value™ is $29.23, compared to a current price of $15.87 — trading 45.7% below its estimated fair value. The current ROCE % is -9.46%. Tandem Diabetes Care's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Tandem Diabetes Care (LTS:0M0F), the current ROCE % is -9.46% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tandem Diabetes Care (LTS:0M0F) Overvalued in 2026?

Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued. The current stock price of $15.87 is trading 45.7% below its estimated GF Value™ of $29.23. GuruFocus considers Tandem Diabetes Care to be Possible Value Trap.

Key valuation signals for LTS:0M0F:

ROCE %: -9.46%
GF Value™: $29.23 vs. price of $15.87 (45.7% below fair value)
GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the LTS:0M0F stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tandem Diabetes Care Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies ATEC BFLY INSP IRMD AVNS IART AORT CNMD ENOV AHCO ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Other Exchanges TNDM:USA TD5A:Germany T2ND34:Brazil

Address 12400 High Bluff Drive, San Diego, CA, USA, 92130

Website https://www.tandemdiabetes.com

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.

67GF Score

Get the complete analysis for LTS:0M0F

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.87

Price

$29.23

GF Value

View LTS:0M0F Analysis

See ROCE % data for all stocks →